DuPont's Cardiolite
This article was originally published in The Gray Sheet
Executive Summary
Investigators in the 2,456-patient Emergency Room Assessment of Sestamibi for Evaluation of chest pain (ERASE Chest Pain) study report that the Cardiolite test, as part of a chest pain evaluation protocol in the emergency room, can effectively differentiate patients suffering heart attack and in need of intensive cardiac care from those who are not. The data were presented Nov. 9 at the American Heart Association's scientific sessions in Atlanta. Funded by the Agency for Health Care Policy and Research, the study shows that such screening could lead to as much as a 20% reduction in the unnecessary admission rate of patients not in need of cardiac care
You may also be interested in...
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.